QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2)

Saboo, Banshi; Ghosh, Sujoy; Tiwaskar, Mangesh; Chawla, Rajeev

doi:10.1016/j.dsx.2021.102264

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Saboo et al, conducted a retrospective study on Type II DM patients treated with teneligliptin 20 or 40 mg once daily, as a single therapy or as a supplement treatment showing an appreciable glycemic control with no QTc prolongation, which is evident from their ECG report. 14 Mohan et al, teneligliptin provided a similar glycemic control as compared to sitagliptin and reduced the HbA 1c , FBG and PPBG values significantly within 12 weeks of treatment. 15 In Indian individuals with T2DM, both gliptins were shown to be safe and well-tolerated.…”

Section: Discussionmentioning

confidence: 97%

Teneligliptin as an Adjuvant Therapy in Type 2 Diabetic Management: A Prospective Observational Study

Kaliyan,

Thangavel,

Palaniappan

2024

J. Young Pharm.

View full text Add to dashboard Cite

Background: Diabetes Mellitus (DM) is a metabolic disorder with hyperglycemia. Management of diabetes is a global health challenge. The goal of this research was designed to prospectively analyze the safety of Teneligliptin, as a supplement therapy in the management of Type 2 DM in south Indian population. Materials and Methods: 302 subjects with diabetes who received teneligliptin (20 mg, oral dose) for a minimum of two months were varied with teneligliptin received for six months. The baseline data before initiating the teneligliptin treatment has also been assessed in the study and any changes in each study parameter were analyzed after two and six months of teneligliptin therapy, respectively. Efficacy was measured for all the patients after supplemental therapy on teneligliptin and was achieved by calculating FPG, BSPP for two, four, six months and HbA 1c value at the sixth month from the baseline value. Results: The results show that there is a statistically significant FPG, BSPP and HbA 1c values compared to that of the baseline value. It is evident that safety was achieved by supplemental therapy on teneligliptin at the dose of 20 mg. In this study, add-on therapy of teneligliptin with other 3 or 4 oral antidiabetic drugs has been used to control the glucose level. Conclusion: However, there are no hypoglycemic episodes found in our study and hence, it is concluded that teneligliptin achieved good blood glucose control and is well tolerated.

show abstract

Section: Discussionmentioning

confidence: 97%